Can you provide the average price target for KALA BIO INC stock?
6 analysts have analysed KALA and the average price target is 1.53 USD. This implies a price increase of 669.23% is expected in the next year compared to the current price of 0.1989.
KALA BIO INC (KALA) Forecast, Price Target & Analyst Ratings
NASDAQ:KALA • US4831192020
Current stock price
0.1989 USD
+0.01 (+4.08%)
At close:
0.1974 USD
0 (-0.75%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for KALA BIO INC (KALA).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 12, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.31
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$1.53
Upside
+ 669.23%
From current price of $0.20 to mean target of $1.53, Based on 6 analyst forecasts
Low
$1.52
Median
$1.53
High
$1.58
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
6 Wall Street analysts provided a forecast for the next 12 months for KALA. The average price target is 1.53 USD. This implies a price increase of 669.23% is expected in the next year compared to the current price of 0.1989.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
43.33%
KALA was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about KALA.
In the previous month the buy percentage consensus was at a similar level.
KALA was analyzed by 6 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-09-29 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-09-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-11 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-09-08 | Mizuho | Initiate | Outperform |
| 2025-05-23 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-04-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-19 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-05-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-04-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-04-01 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2023-11-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-10 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-05-01 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-04-12 | HC Wainwright & Co. | Maintains | Buy |
| 2023-03-27 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-06 | HC Wainwright & Co. | Maintains | Buy |
| 2022-08-15 | HC Wainwright & Co. | Maintains | Buy |
| 2022-05-24 | HC Wainwright & Co. | Maintains | Buy |
| 2022-05-17 | HC Wainwright & Co. | Maintains | Buy |
| 2021-08-06 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2021-08-06 | HC Wainwright & Co. | Maintains | Buy |
| 2021-05-06 | HC Wainwright & Co. | Maintains | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 12, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.31
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 78.30%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
-63.82%
Next Earnings Summary
KALA is expected to report earnings on 5/12/2026. The consensus EPS estimate for the next earnings is -0.31 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2026 - 2032
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 6.36M 4.78% | 11.24M 76.73% | 3.89M -65.39% | -100.00% | 129.44M | 199.41M 54.06% | ||||||||
| EBITDA YoY % growth | -95.32M -9.09% | -129.27M -35.62% | -81.16M 37.22% | N/A 51.50% | N/A -3.51% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -96.23M -9.08% | -130.25M -35.35% | -81.7M 37.27% | -41.17M 51.45% | -42.456M -3.37% | -43.551M -6.22% | -8.16M 81.26% | -8.804M -7.89% | -8.979M -1.99% | -9.159M -2.00% | -9.342M -2.00% | 61.302M 756.19% | 115.87M 89.02% | |
| Operating Margin | -1,513.05% | -1,158.81% | -2,100.26% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 47.36% | 58.11% | |
| EPS YoY % growth | -100.50 27.17% | -108.50 -7.96% | -30.22 72.15% | -18.39 40.64% | -11.05 38.57% | -6.57 57.80% | -1.26 72.80% | -0.41 67.74% | N/A | N/A | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.31 78.30% | -0.30 82.70% | -0.34 60.86% | -0.33 51.28% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -2.04M 80.88% | -2.04M 81.50% | -2.04M 65.00% | -2.04M 77.78% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
KALA BIO INC / KALA Forecast FAQ
What is the next earnings date for KALA stock?
KALA BIO INC (KALA) will report earnings on 2026-05-12, before the market open.
Can you provide the consensus estimates for KALA BIO INC next earnings?
The consensus EPS estimate for the next earnings of KALA BIO INC (KALA) is -0.31 USD and the consensus revenue estimate is 0 USD.
What is the consensus rating for KALA stock?
The consensus rating for KALA BIO INC (KALA) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.